Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

J Immunother Cancer · 2022 · PMC9422817 · PMID 36007963

Europe PMC DOI

hedged sentences

0.0780

closest p · 1.6× alpha

0.1300

boldest claim

The sentences

showed a trendp=0.078so close (0.05 < p ≤ 0.1)

Of note, the frequency of T regulatory cells, defined as CD3 + CD8 - FoxP3 + , showed a trend toward increasing OT in the paired cases ( figure 4E , p=0.078, n=12 BL, 9 OT cases with nine pairs).

also in 53,322 other papers

did not reach statistical significancep=0.13not close (p > 0.1)

CD73 was observed to be strongly induced in three out of four pairs but did not reach statistical significance ( figure 5D , p=0.13).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.